Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to “Sector Perform” at Royal Bank of Canada
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...
BioSpace20h
Biotech’s ‘Worst Fear’ Comes True as FDA’s Marks Departs, Sending Shares Tumbling
Already reeling from years of market chaos, the announced departure of CBER chief Peter Marks sent a ripple across biopharma ...
Sarepta price target lowered to $179 from $210 at BofA
BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the departure of Peter Marks from the FDA’s Center for Biologics ...
Managed Healthcare Executive21h
Wave’s Duchenne Therapy Has Promising Phase 2 Results
Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.
Biotech stocks slide as Marks resignation seen being negative for sector
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food ...